References (by section)

Background

[1] eMedice.com, Vibhuti N Singh, MD, MPH, FACC, "Coronary Artery Athersclerosis"

[2]Lecture Notes, Kevin Korr M.D. Lecture, Brown Univesity, 3/9/2004

Bare Metal Stents

[1] West Suburban Cardiologists, Ltd., “Coronary Stents”

[2] Angioplasty.org, “Balloons and Stents”

[3] Angioplasty.org, “Drug-Eluting Stents”

[4] Guidant Foundation, “MULTI-LINK Vision Coronary Stent System”

[5] Boston Scientific, “Drug-Eluting Stenting”

[6] Escaned, J., et al . “Long-Term Angiographic Results of Stenting in Chronic Total Occlusions:Influence of Stent Design And Vessel Size”. Am Heart J 2004. 138 (4):675-680.

[7] U.S. Patent 5288711. Mitchell, et al . February 22, 1994 .

Drug Eluting Stents

[1]Edith Mathiowitz, Encyclopedia of Controlled Drug Delivery Volume II, Section R

[2]Edith Mathiowitz, Encylcopedia of Controlled Drug Delivery, Volume I, Section H

[3]U.S. Patent Number 5,288,711, Robert D. Mitchell et al. April 28, 192

[4]Cordis V. Boston Scientific, Preliminary Injunction, Civil Action No. 03-027-SLR and Civil Action No. 03-283-SLR, excerpt at www.angioplasty.org

[5]Cypher IFU, Cordis Corporation

Drugs and Pharmacokinetics

[1] Fattori R, & Piva T. Drug-eluting stents in vascular intervention. The Lancet 2003. 361 ; 247-9.

[2] Tanabe K, Regar E, et al . Local drug delivery using coated stents: new developments and future perspectives. Current Pharmaceutical Design 2004. 10 : 357-67.

[3]Current Interventional Cardiology Reports, Sjoerd H Hofma MD, "Recent Developments in Coated Stents"

[4]Medscape Cardiology, Luis Gruberg, MD, "Recent Advances in Stents"

[5]Lecture, Donald Bairn , MD., "Drug Eluting Stents - A New Standard of Care"

[6]Cypher IFU, Cordis Corporation

Products and Clinical Trials

[1] Hall, John. Healthcare Purchasing News: “Drug Eluting Stents: the high cost of Immortality?”

[2] Sternberg, Steve. USA Today: “A New Stent for Angioplasty”.

[3] Cypher IFU

[4] Taxus Express 2 Paclitaxel-Eluting Coronary Stent System – Instructions for Use

[5] Medline Plus Drug Information: Paclitaxel

[6] Taxus Express2 Paclitaxel-Eluting Coronary Stent System – Angioplasty.org

[7] TAXUS Express 2 Paclitaxel-Eluting Stent Program Q&A

[8] The Street: “ Boston Scientific Up on Stent Sales”

Products in Development

[1] Guidant Corporation press release, New York , Nov. 19, 2003 .

[2] Grube E, & Buellesfeld L. Rampamycin analogs for stent-based local drug delivery everolimus- and tacrolimus-eluting stents. Herz 2004. Mar; 29 (2): 162-6.

[3] http://www.texasheartinstitute.org/cme/aha03/baim1.html

[4] United States Patent # 6,716,445. Won, et al . April 6, 2004 .

[5] United States Patent # 6,702,850. Byun, et al . March 9, 2004 .

Implications

[1] Donald Bairn , MD. http://www.texasheartinstitute.org/cme/aha03/baim1.html

[2] Holmes DR , Firth BG, Wood DL. Paradigm shifts in cardiovascular medicine . J Am Col Cardiol 2004. 43 (4): 507-12.

[3] American Heart Association. Heart Disease and Stroke Statistics – 2003 Update. Dallas , TX : American Heart Association, 2002.

[4] Centers for Medicare and Medicaid Services Data Compendium. http://www.cms.hhs.gov

[5] Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to? J Am Col Cardiol 2004. 43 (4): 513-18.

[6] Ferreira AC, Peter AA, Salerno TA, et al . Clinical impact of drug-eluting stents in changing referral practices for coronary surgical revascularization in a tertiary care center. Ann Thorac Surg 2003. 75 : 485-9.

Further Reading

For more detailed references or further questions, please contact Nick Mark.